APA (7th ed.) Citation

H, Y., J, M., E, F., WI, B., JM, B., M, N., . . . RM, R. (2022). Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: Final results of the LYRA study. Leukemia & lymphoma, 63(10), 2383. https://doi.org/10.1080/10428194.2022.2076847

Chicago Style (17th ed.) Citation

H, Yimer, et al. "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Multiple Myeloma: Final Results of the LYRA Study." Leukemia & Lymphoma 63, no. 10 (2022): 2383. https://doi.org/10.1080/10428194.2022.2076847.

MLA (9th ed.) Citation

H, Yimer, et al. "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Multiple Myeloma: Final Results of the LYRA Study." Leukemia & Lymphoma, vol. 63, no. 10, 2022, p. 2383, https://doi.org/10.1080/10428194.2022.2076847.